There are 2137 resources available
1543P - Clinical relevance of somatic and germline alterations in patients with pancreatic ductal adenocarcinoma
Presenter: Fei Wang
Session: E-Poster Display
Resources:
Abstract
1544P - Use of pharmacokinetic parameters of preoperative 5-FU as a prognostic factor in resected pancreatic cancer
Presenter: Anna Vilalta
Session: E-Poster Display
Resources:
Abstract
1545P - DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
Presenter: Helena Verdaguer
Session: E-Poster Display
Resources:
Abstract
1546P - Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer
Presenter: Furkan Ceylan
Session: E-Poster Display
Resources:
Abstract
1547P - Project Survival®: High-fidelity longitudinal phenotypic and multi-omic characterization of pancreatic ductal adenocarcinoma (PDAC) for biomarker discovery
Presenter: A. Moser
Session: E-Poster Display
Resources:
Abstract
1548P - Favourable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer
Presenter: Josef Dvorak
Session: E-Poster Display
Resources:
Abstract
1549P - Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients
Presenter: Daniel Acosta Eyzaguirre
Session: E-Poster Display
Resources:
Abstract
1550P - Combination therapy of low molecular weight heparins, chemotherapy and immunotherapy induce antitumor activity in pancreatic cancer
Presenter: Michail Karamouzis
Session: E-Poster Display
Resources:
Abstract
1551P - Validation of response and survival biomarkers in a phase II trial of BPM 31510-IV in advanced refractory pancreatic ductal adenocarcinoma (PDAC)
Presenter: Vivek Subbiah
Session: E-Poster Display
Resources:
Abstract
1552P - Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX
Presenter: Esther Schwarzenbacher
Session: E-Poster Display
Resources:
Abstract